pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,689 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1183Endpoints903BioPharma Dive347BioSpace317Fierce Biotech301onclive165raps106globenewswire health
therapy area
allOncology7753Rare Disease1891Cardiology1779Immunology1511Hematology1328Vaccines1204Pulmonology
  • Public health must address the rapidly growing Amish population, experts say
    The STAT First Opinion podcast highlighted that the Amish community is expanding quickly, roughly doubling every two decades, which will increasingly affect public health planning. Researchers Bra…
    STAT · 3mo agoNeutral↗ source
  • Roche reports narrow failure of breast cancer pill in Phase 3 trial at ASCO
    Roche updated investors and the oncology community that its experimental breast cancer oral therapy did not meet its primary endpoint in a pivotal Phase 3 study. The data, presented at the America…
    Endpoints · 3mo agoNegative readoutNegative↗ source
← prev
page 78 of 108
next →
73
fda medwatch66
fda recalls64
fda press38
1200
Psychiatry & CNS870
Ophthalmology503
Pain483
Endocrinology & Metabolism481
Infectious Disease444
  • Allen Institute launches multi-hundred-million-dollar effort to turn brain atlas data into neurodegenerative drug candidates
    The Allen Institute, a Seattle nonprofit known for basic brain research, announced a major new effort to move its brain‑atlas knowledge toward drug development. The program will invest several hun…
    Endpoints · 3mo agoPositive↗ source
  • FDA issues draft guidance outlining data flexibilities for cell and gene therapy developers
    The FDA released a draft guidance from its Center for Biologics Evaluation and Research (CBER) that clarifies how developers of cell and gene therapies can use existing data and prior knowledge in…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027
    NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…
    Endpoints · 3mo agoDealPositive↗ source
  • Longevity startup NewLimit secures $435 million Series C as it prepares first liver drug trial
    NewLimit, a longevity‑focused biotech founded in 2021, announced a Series C financing that brought in $435 million, pushing its valuation to about $3.1 billion. The round was led by Founders Fund…
    STAT · 3mo agoDealPositive↗ source
  • Radiopharmaceutical shows promise after Pluvicto; Vera Therapeutics gains FDA agreement to speed IgA nephropathy data analysis
    A new radiopharmaceutical is generating interest for use after patients have completed Pluvicto therapy, suggesting a potential follow‑on treatment option. Abivax reported encouraging results from…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gel
    Contraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million. The capital will be used to advance its candidate, referred to as NES…
    Endpoints · 3mo agoDealPositive↗ source
  • Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipeline
    Travere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…
    Endpoints · 3mo agoDealPositive↗ source
  • Legend Biotech reports first in vivo CAR-T data from Chinese lymphoma trial
    Legend Biotech has released its first in vivo CAR-T cell therapy data, marking the next step after its CAR-T product Carvykti. The data come from an investigator-initiated trial in China that enro…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Eli Lilly warns 340B hospitals to submit claims data within five days or lose price discounts
    Eli Lilly has given roughly 50 hospitals that participate in the federal 340B drug discount program a five‑day deadline to provide comprehensive claims data. The company says that if the data are n…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Trump administration releases Medicaid work-requirement rules, prompting state compliance challenges
    The Morning Rounds newsletter highlighted several health‑policy developments, notably new Medicaid work‑requirement rules and fast‑tracked funding for experimental Ebola vaccines. The Trump admini…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Celcuity reports combo regimen with gedatolisib doubles progression‑free survival odds in late‑stage breast cancer
    Celcuity announced at ASCO 2026 that its experimental drug gedatolisib, used in a combination regimen, showed a significant improvement in a late‑stage breast cancer trial. The data revealed that…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Michigan lawmakers introduce bipartisan bill to curb China-U.S. biotech partnerships
    A bipartisan group of Michigan legislators has unveiled a new bill aimed at limiting cross-border transactions between Chinese and American biotechnology firms. The proposal, introduced by Rep. Jo…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concerns
    Abivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission. The company emphasized th…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • States tighten rules on corporate telehealth, targeting business structures behind direct-to-consumer care
    Telehealth has grown into a multibillion‑dollar industry, with brands like Hims & Hers and Teladoc becoming widely recognized. Despite their visibility, many patients are unaware that corporate te…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Praxis Precision Medicines reports late-stage failure of seizure drug and pauses second trial
    Praxis Precision Medicines had enjoyed a period of momentum, reporting two notable clinical successes in the past eight months. The company’s pipeline had been viewed positively by investors and an…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Eli Lilly gives hospitals five days to meet new 340B claims data policy or lose discounts
    Eli Lilly has told a group of hospitals they must adhere to a new claims data policy within five days or their participation in the 340B drug discount program will be terminated. The policy requir…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • ASCO 2026 hints at future role for VEGF-targeted cancer drugs as complement to immunotherapy
    At the recent ASCO meeting, experts discussed the outlook for VEGF-targeted therapies in oncology. Earlier hopes that this new class could match the blockbuster success of pembrolizumab (Keytruda)…
    Endpoints · 3mo agoNeutral↗ source
  • Fulcrum Therapeutics abandons its only sickle cell drug after FDA cites concerns linked to withdrawn cancer therapy
    Fulcrum Therapeutics announced it is ending development of its sole clinical‑stage sickle cell medicine. The move follows feedback from the U.S. Food and Drug Administration that referenced a rece…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Obesity care startup Ilant Health secures $15M Series A funding
    Ilant Health, a startup focused on obesity care, announced a $15 million Series A financing round. The capital will be used to broaden its personalized treatment platform, which leverages virtual…
    Endpoints · 3mo agoDealPositive↗ source
  • Telemedicine surge could eliminate traditional doctor’s office waiting rooms
    Emergency physician Iyesatta Massaquoi Emeli reflects on how the concept of waiting has been built into medical practice, from the lobby to the triage process, shaping patients' experience of care.…
    STAT · 3mo agoPositive↗ source
  • Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myeloma
    At ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma. The report covered 18 patients treated with the therapy, all of whom showed encouraging outcom…
    Endpoints · 3mo agoDealPositive↗ source
  • Medicare launches $50/month coverage for Wegovy and Zepbound but withholds cost to taxpayers
    Medicare announced a temporary “GLP-1 Bridge” program that will allow adults 65 and older to receive the obesity treatments Wegovy and Zepbound for $50 a month beginning July 1. The program runs t…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis pill shows high remission rates but cancer cases spark safety worries
    Abivax reported that its experimental oral therapy for ulcerative colitis achieved strong efficacy in a Phase 3 maintenance trial involving 580 patients who had previously responded in shorter stud…
    STAT · 3mo agoNegative readoutNegative↗ source